OptimizeRx Corp. (NASDAQ:OPRX) Given Average Rating of “Moderate Buy” by Analysts

OptimizeRx Corp. (NASDAQ:OPRX) has been assigned an average recommendation of “Moderate Buy” from the nine ratings firms that are presently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and six have given a buy recommendation to the company. The average 12 month target price among analysts that have covered the stock in the last year is $11.4286.

A number of analysts recently weighed in on OPRX shares. UBS Group set a $11.00 target price on shares of OptimizeRx in a report on Friday, August 14th. Zacks Research downgraded OptimizeRx from a “strong-buy” rating to a “hold” rating in a report on Monday, May 4th. Citizens Jmp increased their price target on OptimizeRx from $9.00 to $11.00 and gave the company a “market outperform” rating in a research report on Friday, August 14th. Lake Street Capital cut their price objective on OptimizeRx from $20.00 to $11.00 and set a “buy” rating on the stock in a report on Wednesday, May 13th. Finally, Stephens reduced their price objective on shares of OptimizeRx from $10.00 to $7.00 and set an “equal weight” rating for the company in a research note on Wednesday, May 13th.

OptimizeRx Trading Up 2.7%

OptimizeRx stock opened at $7.86 on Wednesday. OptimizeRx has a 1 year low of $4.54 and a 1 year high of $22.25. The firm’s 50-day moving average is $6.50 and its 200-day moving average is $6.55. The company has a debt-to-equity ratio of 0.14, a quick ratio of 5.58 and a current ratio of 5.58. The company has a market cap of $148.08 million, a P/E ratio of 34.18 and a beta of 1.08.

OptimizeRx (NASDAQ:OPRX) last released its quarterly earnings results on Wednesday, August 12th. The company reported $0.16 earnings per share for the quarter, beating analysts’ consensus estimates of $0.11 by $0.05. The company had revenue of $20.50 million for the quarter, compared to analysts’ expectations of $20.20 million. OptimizeRx had a return on equity of 9.44% and a net margin of 4.66%. On average, equities analysts expect that OptimizeRx will post 0.51 earnings per share for the current year.

Hedge Funds Weigh In On OptimizeRx

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in OPRX. AWM Investment Company Inc. purchased a new position in shares of OptimizeRx during the second quarter valued at $1,375,000. Bank of New York Mellon Corp acquired a new stake in OptimizeRx during the 2nd quarter worth about $370,000. Segall Bryant & Hamill LLC acquired a new stake in OptimizeRx during the 1st quarter worth about $1,185,000. Quantinno Capital Management LP grew its stake in OptimizeRx by 180.1% during the 1st quarter. Quantinno Capital Management LP now owns 49,022 shares of the company’s stock valued at $308,000 after acquiring an additional 31,518 shares in the last quarter. Finally, Rice Hall James & Associates LLC grew its stake in OptimizeRx by 1.9% during the 1st quarter. Rice Hall James & Associates LLC now owns 601,921 shares of the company’s stock valued at $3,780,000 after acquiring an additional 11,247 shares in the last quarter. Institutional investors and hedge funds own 76.47% of the company’s stock.

About OptimizeRx

OptimizeRx, Inc is a healthcare technology company that operates a digital health network designed to facilitate communication between pharmaceutical manufacturers, payers and healthcare providers. Through its cloud-based platform, OptimizeRx delivers targeted digital interventions—such as patient savings messages, clinical content and product information—directly into electronic health record (EHR) workflows at the point of care. By integrating with leading EHR systems, the company helps life sciences organizations optimize brand engagement, improve patient adherence and support informed prescribing decisions.

The company’s core offerings include digital prescription benefit notifications, co-pay assistance alerts and real-time clinical messaging tailored to specific patient populations.